New drug combo shows promise for Hard-to-Treat breast cancer

This study tests whether adding the drug pyrotinib to standard chemotherapy before surgery can improve outcomes for women with stage II to III hormone receptor-positive, HER2-negative breast cancer that also has high levels of the HER4 protein. About 140 participants will receive either pyrotinib or a placebo alongside chemotherapy, and researchers will measure how much cancer remains after treatment. The goal is to see if this combination leads to a better response and fewer cancer cells left behind.